Buy Or Sell Opportunity • Jul 30
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 3.0% to PK₨35.06. The fair value is estimated to be PK₨44.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • May 01
Third quarter 2026 earnings released: PK₨0.03 loss per share (vs PK₨0.14 loss in 3Q 2025) Third quarter 2026 results: PK₨0.03 loss per share (improved from PK₨0.14 loss in 3Q 2025). Revenue: PK₨29.2m (up 98% from 3Q 2025). Net loss: PK₨3.96m (loss narrowed 59% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings. Ankündigung • Apr 23
Liven Pharma Limited to Report Q3, 2026 Results on Apr 29, 2026 Liven Pharma Limited announced that they will report Q3, 2026 results on Apr 29, 2026 New Risk • Mar 03
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: PK₨2.68b (US$9.59m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-PK₨34m free cash flow). Earnings have declined by 61% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (PK₨85m revenue, or US$302k). Market cap is less than US$10m (PK₨2.68b market cap, or US$9.59m). Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change). New Risk • Mar 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -PK₨34m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-PK₨34m free cash flow). Earnings have declined by 61% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (PK₨85m revenue, or US$303k). Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (PK₨3.17b market cap, or US$11.3m). Reported Earnings • Mar 01
Second quarter 2026 earnings released: EPS: PK₨0.30 (vs PK₨0.56 loss in 2Q 2025) Second quarter 2026 results: EPS: PK₨0.30 (up from PK₨0.56 loss in 2Q 2025). Revenue: PK₨54.6m (up 219% from 2Q 2025). Net income: PK₨28.2m (up PK₨55.3m from 2Q 2025). Profit margin: 52% (up from net loss in 2Q 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 46% per year, which means it is well ahead of earnings. Ankündigung • Feb 19
Liven Pharma Limited to Report First Half, 2026 Results on Feb 26, 2026 Liven Pharma Limited announced that they will report first half, 2026 results on Feb 26, 2026 Reported Earnings • Jan 04
First quarter 2026 earnings released: PK₨0.32 loss per share (vs PK₨12.17 profit in 1Q 2025) First quarter 2026 results: PK₨0.32 loss per share (down from PK₨12.17 profit in 1Q 2025). Net loss: PK₨30.2m (down 120% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Dec 26
Liven Pharma Limited to Report Q1, 2026 Results on Jan 02, 2026 Liven Pharma Limited announced that they will report Q1, 2026 results at 9:30 AM, Pakistan Standard Time on Jan 02, 2026 New Risk • Dec 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (PK₨127m revenue, or US$454k). Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Market cap is less than US$100m (PK₨4.84b market cap, or US$17.3m). New Risk • Nov 08
New major risk - Revenue and earnings growth Earnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (PK₨127m revenue, or US$453k). Minor Risk Market cap is less than US$100m (PK₨5.16b market cap, or US$18.4m). Ankündigung • Nov 06
Liven Pharmaceuticals Limited, Annual General Meeting, Nov 26, 2025 Liven Pharmaceuticals Limited, Annual General Meeting, Nov 26, 2025. Location: at 49-km lahore, multan road, Pakistan Ankündigung • Oct 31
Liven Pharmaceuticals Limited to Report Fiscal Year 2025 Results on Nov 05, 2025 Liven Pharmaceuticals Limited announced that they will report fiscal year 2025 results at 12:30 PM, Pakistan Standard Time on Nov 05, 2025 Ankündigung • Sep 13
Liven Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of PKR 200 million. Liven Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of PKR 200 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 20,000,000
Price\Range: PKR 10
Transaction Features: Rights Offering Valuation Update With 7 Day Price Move • Jul 17
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to PK₨74.57, the stock trades at a trailing P/E ratio of 64.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in Pakistan. Total returns to shareholders of 433% over the past three years. Valuation Update With 7 Day Price Move • Jun 26
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to PK₨66.04, the stock trades at a trailing P/E ratio of 57x. Average trailing P/E is 22x in the Pharmaceuticals industry in Pakistan. Total returns to shareholders of 426% over the past three years. Valuation Update With 7 Day Price Move • May 15
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to PK₨62.34, the stock trades at a trailing P/E ratio of 53.8x. Average trailing P/E is 17x in the Pharmaceuticals industry in Pakistan. Total returns to shareholders of 369% over the past three years. Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to PK₨63.00, the stock trades at a trailing P/E ratio of 51.6x. Average trailing P/E is 22x in the Pharmaceuticals industry in Pakistan. Total returns to shareholders of 412% over the past three years. Valuation Update With 7 Day Price Move • Feb 18
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to PK₨117, the stock trades at a trailing P/E ratio of 77.9x. Average trailing P/E is 24x in the Pharmaceuticals industry in Pakistan. Total returns to shareholders of 406% over the past three years. New Risk • Feb 07
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 6x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). High level of non-cash earnings (27% accrual ratio). Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (PK₨89m revenue, or US$319k). Minor Risk Market cap is less than US$100m (PK₨12.4b market cap, or US$44.4m). Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to PK₨137, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 24x in the Pharmaceuticals industry in Pakistan. Total returns to shareholders of 606% over the past three years. Valuation Update With 7 Day Price Move • Jan 07
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to PK₨198, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 23x in the Pharmaceuticals industry in Pakistan. Total returns to shareholders of 827% over the past three years. Valuation Update With 7 Day Price Move • Dec 10
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to PK₨49.82, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 10x in the Luxury industry in Pakistan. Total returns to shareholders of 160% over the past three years. Valuation Update With 7 Day Price Move • Nov 20
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to PK₨43.00, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 9x in the Luxury industry in Pakistan. Total returns to shareholders of 89% over the past three years. Ankündigung • Oct 08
Landmark Spinning Industries Limited, Annual General Meeting, Oct 25, 2024 Landmark Spinning Industries Limited, Annual General Meeting, Oct 25, 2024. Location: at the registered office of the company, situated at 1st floor,cotton exchange building, i.i.chundrigar road, karachi Pakistan Board Change • May 14
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 22
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Mar 11
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Jan 19
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Nov 28
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Oct 13
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Sep 08
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Jul 21
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Jun 21
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 20
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Mar 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Feb 08
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Nov 23
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Oct 21
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Sep 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Mar 29
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Feb 21
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Muhammad Ameen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Executive Departure • Aug 03
CFO & Company Secretary Yousuf Noorani has left the company On the 24th of July, Yousuf Noorani's tenure as CFO & Company Secretary ended. We don't have any record of a personal shareholding under Yousuf's name. A total of 2 executives have left over the last 12 months. Executive Departure • Mar 05
Independent Director has left the company On the 26th of February, Anwer Ali's tenure as Independent Director ended after 3.9 years in the role. As of December 2020, Anwer personally held only 1.00k shares (PK₨14k worth at the time). Anwer is the only executive to leave the company over the last 12 months. Ankündigung • Feb 28
Landmark Spinning Industries Limited Announces Board Changes Landmark Spinning Industries Limited at the board of directors meeting held on February 26, 2021, approved the appointment of Muhammad Ameen an independent director in place of Mr. Anwer Ali, resigned. The board has filled the casual vacancy of director is for the remaining term of 3 years, as defined by the companies act 2017. Further more, under the corporate governance, the audit and HR committee be and are hereby reconstitute by inducting an independent director, Muhammad Ameen along with two other directors namely Mr. Abdulla Hahswani, and Mrs. Shahrina Khawaja Hashwani. Is New 90 Day High Low • Feb 03
New 90-day high: PK₨22.00 The company is up 49% from its price of PK₨14.79 on 02 November 2020. The Pakistani market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 29% over the same period. 
